Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Prostate Cancer

  Free Subscription

Articles published in Cancer Lett

Retrieve available abstracts of 93 articles:
HTML format

Single Articles

    July 2021
  1. GAO Y, Liu Y, Liu Y, Peng Y, et al
    UHRF1 promotes androgen receptor-regulated CDC6 transcription and anti-androgen receptor drug resistance in prostate cancer through KDM4C-Mediated chromatin modifications.
    Cancer Lett. 2021;520:172-183.
    PubMed     Abstract available

  2. LIANG J, Wang L, Poluben L, Nouri M, et al
    Androgen receptor splice variant 7 functions independently of the full length receptor in prostate cancer cells.
    Cancer Lett. 2021 Jul 10. pii: S0304-3835(21)00340.
    PubMed     Abstract available

    June 2021
  3. YAMADA Y, Beltran H
    The treatment landscape of metastatic prostate cancer.
    Cancer Lett. 2021 Jun 18. pii: S0304-3835(21)00295.
    PubMed     Abstract available

  4. JAMROZE A, Chatta G, Tang DG
    Androgen receptor (AR) heterogeneity in prostate cancer and therapy resistance.
    Cancer Lett. 2021;518:1-9.
    PubMed     Abstract available

    May 2021
  5. HOU Z, Huang S, Li Z
    Androgens in prostate cancer: A tale that never ends.
    Cancer Lett. 2021;516:1-12.
    PubMed     Abstract available

  6. FREELAND J, Crowell PD, Giafaglione JM, Boutros PC, et al
    Aging of the progenitor cells that initiate prostate cancer.
    Cancer Lett. 2021;515:28-35.
    PubMed     Abstract available

    February 2021
  7. LLOPIZ D, Ruiz M, Silva L, Reparaz D, et al
    Inhibition of adjuvant-induced TAM receptors potentiates cancer vaccine immunogenicity and therapeutic efficacy.
    Cancer Lett. 2021;499:279-289.
    PubMed     Abstract available

  8. KUMAR S, Prajapati KS, Singh AK, Kushwaha PP, et al
    Long non-coding RNA regulating androgen receptor signaling in breast and prostate cancer.
    Cancer Lett. 2021 Feb 5. pii: S0304-3835(20)30637.
    PubMed     Abstract available

    January 2021
  9. SONG J, Yu J, Jeong LS, Lee SK, et al
    A Novel cytarabine analog evokes synthetic lethality by targeting MK2 in p53-deficient cancer cells.
    Cancer Lett. 2021;497:54-65.
    PubMed     Abstract available

  10. CHEN L, Wang YY, Li D, Wang C, et al
    LMO2 upregulation due to AR deactivation in cancer-associated fibroblasts induces non-cell-autonomous growth of prostate cancer after androgen deprivation.
    Cancer Lett. 2021 Jan 24. pii: S0304-3835(21)00034.
    PubMed     Abstract available

    November 2020
  11. LEECH M, Osman S, Jain S, Marignol L, et al
    Mini review: Personalization of the radiation therapy management of prostate cancer using MRI-based radiomics.
    Cancer Lett. 2020 Nov 4. pii: S0304-3835(20)30565.
    PubMed     Abstract available

    September 2020
  12. NIKHIL K, Kamra M, Raza A, Shah K, et al
    Negative cross talk between LIMK2 and PTEN promotes castration resistant prostate cancer pathogenesis in cells and in vivo.
    Cancer Lett. 2020 Sep 12. pii: S0304-3835(20)30472.
    PubMed     Abstract available

    August 2020
  13. WANG J, Xu W, Wang B, Lin G, et al
    GLUT1 is an AR target contributing to tumor growth and glycolysis in castration-resistant and enzalutamide-resistant prostate cancers.
    Cancer Lett. 2020;485:45-55.
    PubMed     Abstract available

  14. CHEN D, Chou FJ, Chen Y, Tian H, et al
    Targeting the radiation-induced TR4 nuclear receptor-mediated QKI/circZEB1/miR-141-3p/ZEB1 signaling increases prostate cancer radiosensitivity.
    Cancer Lett. 2020 Aug 5. pii: S0304-3835(20)30396.
    PubMed     Abstract available

    July 2020
  15. BATES M, Boland A, McDermott N, Marignol L, et al
    YB-1: The key to personalised prostate cancer management?
    Cancer Lett. 2020 Jul 15. pii: S0304-3835(20)30361.
    PubMed     Abstract available

    June 2020
  16. ZHANG M, Wang Y, Matyunina LV, Akbar A, et al
    The ability of miRNAs to induce mesenchymal-to-epithelial transition (MET) in cancer cells is highly dependent upon genetic background.
    Cancer Lett. 2020;480:15-23.
    PubMed     Abstract available

    May 2020
  17. WANG S, Gilbreath C, Kollipara RK, Sonavane R, et al
    Mithramycin suppresses DNA damage repair via targeting androgen receptor in prostate cancer.
    Cancer Lett. 2020 May 30. pii: S0304-3835(20)30289.
    PubMed     Abstract available

  18. MIRANDA-GONCALVES V, Lameirinhas A, Henrique R, Baltazar F, et al
    The metabolic landscape of urological cancers: New therapeutic perspectives.
    Cancer Lett. 2020;477:76-87.
    PubMed     Abstract available

    April 2020
  19. SIDDIQUI S, Libertini SJ, Lucas CA, Lombard AP, et al
    The p14ARF tumor suppressor restrains androgen receptor activity and prevents apoptosis in prostate cancer cells.
    Cancer Lett. 2020 Apr 21. pii: S0304-3835(20)30163.
    PubMed     Abstract available

    February 2020
  20. BELLISAI C, Sciamanna I, Rovella P, Giovannini D, et al
    Reverse transcriptase inhibitors promote the remodeling of nuclear architecture and induce autophagy in prostate cancer cells.
    Cancer Lett. 2020 Feb 26. pii: S0304-3835(20)30098.
    PubMed     Abstract available

    December 2019
  21. RAY J, Haughey C, Hoey C, Jeon J, et al
    miR-191 promotes radiation resistance of prostate cancer through interaction with RXRA.
    Cancer Lett. 2019 Dec 21. pii: S0304-3835(19)30639.
    PubMed     Abstract available

  22. XU H, Sun Y, You B, Huang CP, et al
    Androgen receptor reverses the oncometabolite R-2-hydroxyglutarate-induced prostate cancer cell invasion via suppressing the circRNA-51217/miRNA-646/TGFbeta1/p-Smad2/3 signaling.
    Cancer Lett. 2019 Dec 14. pii: S0304-3835(19)30620.
    PubMed     Abstract available

  23. YANG Z, Chen J, Xie H, Liu T, et al
    Androgen receptor suppresses prostate cancer metastasis but promotes bladder cancer metastasis via differentially altering miRNA525-5p/SLPI-mediated vasculogenic mimicry formation.
    Cancer Lett. 2019 Dec 13. pii: S0304-3835(19)30624.
    PubMed     Abstract available

  24. LEE YG, Nam Y, Shin KJ, Yoon S, et al
    Androgen-induced expression of DRP1 regulates mitochondrial metabolic reprogramming in prostate cancer.
    Cancer Lett. 2019 Dec 12. pii: S0304-3835(19)30623.
    PubMed     Abstract available

    November 2019
  25. LIN JZ, Wang WW, Hu TT, Zhu GY, et al
    FOXM1 contributes to docetaxel resistance in castration-resistant prostate cancer by inducing AMPK/mTOR-mediated autophagy.
    Cancer Lett. 2019 Nov 15. pii: S0304-3835(19)30569.
    PubMed     Abstract available

    October 2019
  26. SHEN Z, Zhou L, Zhang C, Xu J, et al
    Reduction of circular RNA Foxo3 promotes prostate cancer progression and chemoresistance to docetaxel.
    Cancer Lett. 2019 Oct 5. pii: S0304-3835(19)30497.
    PubMed     Abstract available

    September 2019
  27. LIANG Z, Cao J, Tian L, Shen Y, et al
    Aromatase-induced endogenous estrogen promotes tumour metastasis through estrogen receptor-alpha/matrix metalloproteinase 12 axis activation in castration-resistant prostate cancer.
    Cancer Lett. 2019 Sep 6. pii: S0304-3835(19)30465.
    PubMed     Abstract available

  28. TSING T, Beretov J, Ni J, Bai X, et al
    Cancer stem cells in prostate cancer radioresistance.
    Cancer Lett. 2019 Sep 4. pii: S0304-3835(19)30457.
    PubMed     Abstract available

    August 2019
  29. XU Y, Deng J, Wang G, Zhu Y, et al
    Long Non-coding RNAs in Prostate Cancer: Functional Roles and Clinical Implications.
    Cancer Lett. 2019 Aug 26. pii: S0304-3835(19)30447.
    PubMed     Abstract available

    June 2019
  30. MAGGIO V, Canovas V, Felix AJ, Gomez V, et al
    A novel DNA-binding motif in prostate tumor overexpressed-1 (PTOV1) required for the expression of ALDH1A1 and CCNG2 in cancer cells.
    Cancer Lett. 2019;452:158-167.
    PubMed     Abstract available

    April 2019
  31. CHEN X, Shi H, Bi X, Li Y, et al
    Targeting the Deubiquitinase STAMBPL1 Triggers Apoptosis in Prostate Cancer Cells by Promoting XIAP Degradation.
    Cancer Lett. 2019 Apr 17. pii: S0304-3835(19)30251.
    PubMed     Abstract available

  32. KAPUR N, Mir H, Sonpavde G, Jain S, et al
    Prostate cancer cells hyper-activate CXCR6 signaling by cleaving CXCL16 to overcome effect of docetaxel.
    Cancer Lett. 2019 Apr 8. pii: S0304-3835(19)30219.
    PubMed     Abstract available

    March 2019
  33. SINGH V, Jaiswal PK, Ghosh I, Koul HK, et al
    The TLK1-Nek1 axis promotes Prostate Cancer progression.
    Cancer Lett. 2019 Mar 27. pii: S0304-3835(19)30197.
    PubMed     Abstract available

  34. XIE H, Liu T, Chen J, Yang Z, et al
    Activation of PSGR with beta-ionone suppresses prostate cancer progression by blocking androgen receptor nuclear translocation.
    Cancer Lett. 2019 Mar 27. pii: S0304-3835(19)30200.
    PubMed     Abstract available

  35. SHAO J, Zhu W, Ding Y, Zhu H, et al
    Phosphorylation of LIFR promotes prostate cancer progression by activating the AKT pathway.
    Cancer Lett. 2019 Mar 6. pii: S0304-3835(19)30128.
    PubMed     Abstract available

  36. LUO J, Tian J, Chou F, Lin C, et al
    Targeting the androgen receptor (AR) with AR degradation enhancer ASC-J9(R) led to increase docetaxel sensitivity via suppressing the p21 expression.
    Cancer Lett. 2019;444:35-44.
    PubMed     Abstract available

    February 2019
  37. GESMUNDO I, Di Blasio L, Banfi D, Villanova T, et al
    Proton pump inhibitors promote the growth of androgen-sensitive prostate cancer cells through ErbB2, ERK1/2, PI3K/Akt, GSK-3beta signaling and inhibition of cellular prostatic acid phosphatase.
    Cancer Lett. 2019 Feb 18. pii: S0304-3835(19)30106.
    PubMed     Abstract available

  38. FOWKE JH, Koyama T, Dai Q, Zheng SL, et al
    Blood and Dietary Magnesium Levels are not linked with lower Prostate Cancer Risk in Black or White Men.
    Cancer Lett. 2019 Feb 15. pii: S0304-3835(19)30101.
    PubMed     Abstract available

  39. FENG Y, Sessions EH, Zhang F, Ban F, et al
    Identification and characterization of small molecule inhibitors of the ubiquitin ligases Siah1/2 in melanoma and prostate cancer cells.
    Cancer Lett. 2019 Feb 13. pii: S0304-3835(19)30084.
    PubMed     Abstract available

  40. ELLIOTT B, Millena AC, Matyunina L, Zhang M, et al
    Essential role of JunD in cell proliferation is mediated via MYC signaling in prostate cancer cells.
    Cancer Lett. 2019 Feb 11. pii: S0304-3835(19)30077.
    PubMed     Abstract available

  41. NIKHIL K, Chang L, Viccaro K, Jacobsen M, et al
    Identification of LIMK2 as a Therapeutic Target in Castration Resistant Prostate Cancer.
    Cancer Lett. 2019 Feb 1. pii: S0304-3835(19)30055.
    PubMed     Abstract available

    January 2019
  42. TIAN J, Guo F, Chen Y, Li Y, et al
    Nanoliposomal formulation encapsulating celecoxib and genistein inhibiting COX-2 pathway and Glut-1 receptors to prevent prostate cancer cell proliferation.
    Cancer Lett. 2019 Jan 20. pii: S0304-3835(19)30014.
    PubMed     Abstract available

  43. CHEN Y, Gera L, Zhang S, Li X, et al
    Small Molecule BKM1972 Inhibits Human Prostate Cancer Growth and Overcomes Docetaxel Resistance in Intraosseous Models.
    Cancer Lett. 2019 Jan 17. pii: S0304-3835(19)30022.
    PubMed     Abstract available

    November 2018
  44. CHENG H, Li X, Wang C, Chen Y, et al
    Inhibition of tankyrase by a novel small molecule significantly attenuates prostate cancer cell proliferation.
    Cancer Lett. 2018 Nov 22. pii: S0304-3835(18)30677.
    PubMed     Abstract available

  45. ZHANG M, Sun Y, Meng J, Zhang L, et al
    Targeting AR-Beclin 1 Complex-Modulated Growth Factor Signaling Increases the Antiandrogen-Enzalutamide Sensitivity to Better Suppress the Castration-Resistant Prostate Cancer Growth.
    Cancer Lett. 2018 Nov 10. pii: S0304-3835(18)30672.
    PubMed     Abstract available

    October 2018
  46. CHEN WY, Zeng T, Wen YC, Yeh HL, et al
    Androgen deprivation-induced ZBTB46-PTGS1 signaling promotes neuroendocrine differentiation of prostate cancer.
    Cancer Lett. 2018 Oct 9. pii: S0304-3835(18)30610.
    PubMed     Abstract available

    September 2018
  47. NIU Y, Guo C, Wen S, Tian J, et al
    ADT with antiandrogens in prostate cancer induces adverse effect of increasing resistance, neuroendocrine differentiation and tumor metastasis.
    Cancer Lett. 2018 Sep 15. pii: S0304-3835(18)30575.
    PubMed     Abstract available

  48. RUSSO JW, Liu X, Ye H, Calagua C, et al
    Phosphorylation of Androgen Receptor Serine 81 is Associated with its Reactivation in Castration-Resistant Prostate Cancer.
    Cancer Lett. 2018 Sep 11. pii: S0304-3835(18)30569.
    PubMed     Abstract available

  49. WANG S, Ekoue DN, Raj GV, Kittler R, et al
    Targeting the turnover of oncoproteins as a new avenue for therapeutics development in castration-resistant prostate cancer.
    Cancer Lett. 2018 Sep 11. pii: S0304-3835(18)30565.
    PubMed     Abstract available

  50. DELLIAUX C, Tian TV, Bouchet M, Fradet A, et al
    TMPRSS2:ERG gene fusion expression regulates bone markers and enhances the osteoblastic phenotype of prostate cancer bone metastases.
    Cancer Lett. 2018 Sep 7. pii: S0304-3835(18)30551.
    PubMed     Abstract available

    August 2018
  51. DALAL K, Ban F, Li H, Morin H, et al
    Selectively targeting the dimerization interface of human androgen receptor with small-molecules to treat castration-resistant prostate cancer.
    Cancer Lett. 2018 Aug 27. pii: S0304-3835(18)30528.
    PubMed     Abstract available

  52. MILLER DR, Tzeng CC, Farmer T, Keller ET, et al
    Novel CIL-102 Derivatives as Potential Therapeutic Agents for Docetaxel-Resistant Prostate Cancer.
    Cancer Lett. 2018 Aug 2. pii: S0304-3835(18)30503.
    PubMed     Abstract available

    June 2018
  53. CHANG YT, Lin TP, Tang JT, Campbell M, et al
    HOTAIR is a REST-regulated lncRNA that promotes neuroendocrine differentiation in castration resistant prostate cancer.
    Cancer Lett. 2018 Jun 23. pii: S0304-3835(18)30435.
    PubMed     Abstract available

    May 2018
  54. KANWAL R, Shukla S, Walker E, Gupta S, et al
    Acquisition of tumorigenic potential and therapeutic resistance in CD133+ subpopulation of prostate cancer cells exhibiting stem-cell like characteristics.
    Cancer Lett. 2018 May 15. pii: S0304-3835(18)30339.
    PubMed     Abstract available

  55. ABISOYE-OGUNNIYAN A, Lin H, Ghebremedhin A, Salam A, et al
    Transcriptional Repressor Kaiso Promotes Epithelial to Mesenchymal Transition and Metastasis in Prostate Cancer through Direct Regulation of miR-200c.
    Cancer Lett. 2018 May 8. pii: S0304-3835(18)30319.
    PubMed     Abstract available

    April 2018
  56. SINGH SK, Lillard JW Jr., Singh R
    Title: Reversal of drug resistance by planetary ball milled (PBM) nanoparticle loaded with resveratrol and docetaxel in prostate cancer.
    Cancer Lett. 2018 Apr 17. pii: S0304-3835(18)30278.
    PubMed     Abstract available

  57. CHANG AC, Chen PC, Lin YF, Su CM, et al
    Osteoblast-secreted WISP-1 promotes adherence of prostate cancer cells to bone via the VCAM-1/integrin alpha4beta1 system.
    Cancer Lett. 2018 Apr 5. pii: S0304-3835(18)30254.
    PubMed     Abstract available

    March 2018
  58. OING C, Tennstedt P, Simon R, Volquardsen J, et al
    BCL2-overexpressing prostate cancer cells rely on PARP1-dependent end-joining and are sensitive to combined PARP inhibitor and radiation therapy.
    Cancer Lett. 2018 Mar 8. pii: S0304-3835(18)30196.
    PubMed     Abstract available

  59. UTTER M, Chakraborty S, Goren L, Feuser L, et al
    Elevated phospholipase D activity in androgen-insensitive prostate cancer cells promotes both survival and metastatic phenotypes.
    Cancer Lett. 2018;423:28-35.
    PubMed     Abstract available

    February 2018
  60. CHHABRA G, Singh CK, Ndiaye MA, Fedorowicz S, et al
    Prostate cancer chemoprevention by natural agents: Clinical evidence and potential implications.
    Cancer Lett. 2018 Feb 19. pii: S0304-3835(18)30158.
    PubMed     Abstract available

  61. LIN W, Luo J, Sun Y, Lin C, et al
    ASC-J9((R)) suppresses prostate cancer cell invasion via altering the sumoylation-phosphorylation of STAT3.
    Cancer Lett. 2018 Feb 6. pii: S0304-3835(18)30132.
    PubMed     Abstract available

  62. GRUNDEMANN C, Huber R
    Chemoprevention with isothiocyanates - From bench to bedside.
    Cancer Lett. 2018;414:26-33.
    PubMed     Abstract available

    January 2018
  63. MENG X, Vander Ark A, Daft P, Woodford E, et al
    Loss of TGF-beta signaling in osteoblasts increases basic-FGF and promotes prostate cancer bone metastasis.
    Cancer Lett. 2018 Jan 11. pii: S0304-3835(18)30040.
    PubMed     Abstract available

  64. LI X, Li J, Cai Y, Peng S, et al
    Hyperglycaemia-induced miR-301a promotes cell proliferation by repressing p21 and Smad4 in prostate cancer.
    Cancer Lett. 2018 Jan 10. pii: S0304-3835(18)30053.
    PubMed     Abstract available

  65. MITOBE Y, Takayama KI, Horie-Inoue K, Inoue S, et al
    Prostate cancer-associated lncRNAs.
    Cancer Lett. 2018 Jan 9. pii: S0304-3835(18)30034.
    PubMed     Abstract available

    December 2017
  66. LIU S, Li X, Lin Z, Su L, et al
    SEC-induced activation of ANXA7 GTPase suppresses prostate cancer metastasis.
    Cancer Lett. 2017;416:11-23.
    PubMed     Abstract available

  67. HU F, Zhao Y, Yu Y, Fang JM, et al
    Docetaxel-mediated autophagy promotes chemoresistance in castration-resistant prostate cancer cells by inhibiting STAT3.
    Cancer Lett. 2017;416:24-30.
    PubMed     Abstract available

  68. CHENG MA, Chou FJ, Wang K, Yang R, et al
    Androgen receptor (AR) degradation enhancer ASC-J9((R)) in an FDA-approved formulated solution suppresses castration resistant prostate cancer cell growth.
    Cancer Lett. 2017 Dec 1. pii: S0304-3835(17)30763.
    PubMed     Abstract available

    November 2017
  69. ZANG Y, Pascal LE, Zhou Y, Qiu X, et al
    ELL2 regulates DNA non-homologous end joining (NHEJ) repair in prostate cancer cells.
    Cancer Lett. 2017 Nov 24. pii: S0304-3835(17)30750.
    PubMed     Abstract available

  70. LEE C, Whang YM, Campbell P, Mulcrone PL, et al
    Dual targeting c-met and VEGFR2 in osteoblasts suppresses growth and osteolysis of prostate cancer bone metastasis.
    Cancer Lett. 2017;414:205-213.
    PubMed     Abstract available

  71. KUMAR S, Singh R, Malik S, Manne U, et al
    Prostate cancer health disparities: An immuno-biological perspective.
    Cancer Lett. 2017;414:153-165.
    PubMed     Abstract available

  72. KOLLURU V, Pal D, Papu John AMS, Ankem MK, et al
    Induction of Plac8 promotes pro-survival function of autophagy in cadmium-induced prostate carcinogenesis.
    Cancer Lett. 2017;408:121-129.
    PubMed     Abstract available

    October 2017
  73. GONZALEZ-CHAVARRIA I, Fernandez E, Gutierrez N, Gonzalez-Horta EE, et al
    LOX-1 activation by oxLDL triggers an epithelial mesenchymal transition and promotes tumorigenic potential in prostate cancer cells.
    Cancer Lett. 2017 Oct 26. pii: S0304-3835(17)30672.
    PubMed     Abstract available

    September 2017
  74. QIN F, Zhang Y, Liu J, Li H, et al
    SLC45A3-ELK4 functions as a long non-coding chimeric RNA.
    Cancer Lett. 2017;404:53-61.
    PubMed     Abstract available

  75. HOANG B, Ernsting MJ, Tang WS, Bteich J, et al
    Cabazitaxel-Conjugated Nanoparticles for Docetaxel-Resistant and Bone Metastatic Prostate Cancer.
    Cancer Lett. 2017 Sep 28. pii: S0304-3835(17)30582.
    PubMed     Abstract available

  76. EL-SAYED IY, Daher A, Destouches D, Firlej V, et al
    Extracellular vesicles released by mesenchymal-like prostate carcinoma cells modulate EMT state of recipient epithelial-like carcinoma cells through regulation of AR signaling.
    Cancer Lett. 2017 Sep 19. pii: S0304-3835(17)30560.
    PubMed     Abstract available

  77. BASHARI O, Redko B, Cohen A, Luboshits G, et al
    Discovery of peptide drug carrier candidates for targeted multi-drug delivery into prostate cancer cells.
    Cancer Lett. 2017 Sep 6. pii: S0304-3835(17)30535.
    PubMed     Abstract available

    August 2017
  78. DATTA A, Kim H, Lal M, McGee L, et al
    Manumycin A suppresses exosome biogenesis and secretion via targeted inhibition of Ras/Raf/ERK1/2 signaling and hnRNP H1 in castration-resistant prostate cancer cells.
    Cancer Lett. 2017 Aug 24. pii: S0304-3835(17)30507.
    PubMed     Abstract available

  79. CHEN J, Li L, Yang Z, Luo J, et al
    Androgen-deprivation therapy with enzalutamide enhances prostate cancer metastasis via decreasing the EPHB6 suppressor expression.
    Cancer Lett. 2017 Aug 18. pii: S0304-3835(17)30491.
    PubMed     Abstract available

  80. KANWAL R, Plaga AR, Liu X, Shukla GC, et al
    MicroRNAs in prostate cancer: Functional role as biomarkers.
    Cancer Lett. 2017 Aug 18. pii: S0304-3835(17)30488.
    PubMed     Abstract available

  81. AHMAD G, El Sadda R, Botchkina G, Ojima I, et al
    Nanoemulsion formulation of a novel taxoid DHA-SBT-1214 inhibits prostate cancer stem cell-induced tumor growth.
    Cancer Lett. 2017;406:71-80.
    PubMed     Abstract available

  82. SHI X, Zhang X, Li J, Zhao H, et al
    PD-1/PD-L1 blockade enhances the efficacy of SA-GM-CSF surface-modified tumor vaccine in prostate cancer.
    Cancer Lett. 2017 Aug 7. pii: S0304-3835(17)30465.
    PubMed     Abstract available

    July 2017
  83. LOGOZZI M, Angelini DF, Iessi E, Mizzoni D, et al
    Increased PSA expression on prostate cancer exosomes in in vitro condition and in cancer patients.
    Cancer Lett. 2017 Jul 8. pii: S0304-3835(17)30418.
    PubMed     Abstract available

    June 2017
  84. GAO F, Alwhaibi A, Sabbineni H, Verma A, et al
    Suppression of Akt1-beta-catenin pathway in advanced prostate cancer promotes TGFbeta1-mediated epithelial to mesenchymal transition and metastasis.
    Cancer Lett. 2017 Jun 7. pii: S0304-3835(17)30374.
    PubMed     Abstract available

  85. LI Q, Ye L, Xin Z, Wang M, et al
    FZD8, a target of p53, promotes bone metastasis in prostate cancer by activating canonical Wnt/beta-catenin signaling.
    Cancer Lett. 2017 Jun 7. pii: S0304-3835(17)30375.
    PubMed     Abstract available

    May 2017
  86. YAN F, Li X, Li N, Zhang R, et al
    Immunoproapoptotic molecule scFv-Fdt-tBid modified mesenchymal stem cells for prostate cancer dual-targeted therapy.
    Cancer Lett. 2017 May 18. pii: S0304-3835(17)30325.
    PubMed     Abstract available

  87. DILLY SJ, Clark AJ, Marsh A, Mitchell DA, et al
    A chemical genomics approach to drug reprofiling in oncology: Antipsychotic drug risperidone as a potential adenocarcinoma treatment.
    Cancer Lett. 2017;393:16-21.
    PubMed     Abstract available

    April 2017
  88. BRIZZOLARA A, Benelli R, Vene R, Barboro P, et al
    The ErbB family and androgen receptor signaling are targets of Celecoxib in prostate cancer.
    Cancer Lett. 2017 Apr 25. pii: S0304-3835(17)30285.
    PubMed     Abstract available

    March 2017
  89. LIN SJ, Chou FJ, Li L, Lin CY, et al
    Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 (ARv7).
    Cancer Lett. 2017 Mar 31. pii: S0304-3835(17)30217.
    PubMed     Abstract available

  90. TAKAYAMA K, Inoue T, Narita S, Maita S, et al
    Inhibition of the RANK/RANKL signaling with osteoprotegerin prevents castration-induced acceleration of bone metastasis in castration-insensitive prostate cancer.
    Cancer Lett. 2017 Mar 31. pii: S0304-3835(17)30216.
    PubMed     Abstract available

  91. O'MALLEY J, Kumar R, Kuzmin A, Pliss A, et al
    Lipid quantification by Raman microspectroscopy as a potential biomarker in prostate cancer.
    Cancer Lett. 2017 Mar 23. pii: S0304-3835(17)30199.
    PubMed     Abstract available

  92. GUO C, Yeh S, Niu Y, Li G, et al
    Targeting Androgen Receptor versus Targeting Androgens to suppress Castration Resistant Prostate Cancer.
    Cancer Lett. 2017 Mar 18. pii: S0304-3835(17)30195.
    PubMed     Abstract available

  93. KANG TS, Wang W, Zhong HJ, Dong ZZ, et al
    An anti-prostate cancer benzofuran-conjugated iridium(III) complex as a dual inhibitor of STAT3 and NF-kappaB.
    Cancer Lett. 2017 Mar 16. pii: S0304-3835(17)30180.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.